Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
60%(3 trials)

Phase Distribution

Ph phase_2
1
20%
Ph phase_1
1
20%
Ph phase_3
1
20%
Ph phase_4
2
40%

Phase Distribution

1

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
1(20.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Phase 4Post-market surveillance
2(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (20.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Phase 42 (40.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_3

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

NCT04490499
completedphase_2

Hepatitis B Vaccine for Non-responders

NCT03415672
completedphase_1

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

NCT02540538
completedphase_4

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

NCT00684671
completedphase_4

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

NCT00603252

Clinical Trials (5)

Showing 5 of 5 trials
NCT04490499Phase 3

A Hepatitis B Vaccine Challenge Study After Previous Vaxelis® Vaccination (V419-013)

Completed
NCT03415672Phase 2

Hepatitis B Vaccine for Non-responders

Completed
NCT02540538Phase 1

Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders

Completed
NCT00684671Phase 4

Evaluation of Immune Memory to Twinrix or Comparator by Challenge Dose Administration 4 Years After Primary Vaccination

Completed
NCT00603252Phase 4

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5